赛伦生物回复称，在抗血清抗毒素技术领域，除了针对蜂毒、蛇毒毒素中毒布局的抗血清新药研发项 目，公司尚未在其他动物毒素中毒上布局新药项目。如有正式立项的新药研发项目，公司将在定期报告 中进行披露。 格隆汇2月27日｜有投资者在互动平台向赛伦生物提问：恭喜公司抗蜂毒血清新药申请获受理，请问公 司是否考虑将抗毒素技术平台拓展到其他领域，比如蝎毒、蜘蛛毒等。公司在更广泛的特种免疫制剂领 域有无布局设想？ ...

Core Insights - India accounts for approximately 50% of global snakebite fatalities, with around 50,000 deaths annually, and a total of up to 1.2 million deaths over the past 20 years [1] - The high mortality rate is attributed to inadequate government attention, poor infrastructure, and prevalent superstitions among the population [1] - The World Health Organization has prioritized snakebite envenoming as a neglected tropical disease to enhance governmental focus [1] Group 1 - Timely administration of antivenom is crucial for treating snakebites, as delays can lead to severe complications such as respiratory failure and irreversible organ failure [2] - India faces challenges with limited and non-specific antivenom availability, as current antivenoms only address bites from four major snake species, while the country has a diverse range of venomous snakes [2] - The National Action Plan for Prevention and Control of Snakebite Envenoming was launched in 2024, aiming to halve snakebite fatalities by 2030 through improved monitoring, increased antivenom supply, and public awareness campaigns [2]

Group 1 - The core viewpoint of the article highlights that the company's fourth-quarter revenue was low, which negatively impacted its quarterly profit due to the seasonal nature of its main products, antivenom and tetanus immunoglobulin [1] - The company noted that the incidence rates of snake bites and trauma are significantly higher in summer, leading to larger sales volumes in the second and third quarters, while the first and fourth quarters see lower sales [1] - The company is actively seeking quality acquisition targets to promote its external growth strategy, aligning with its development needs and external environmental conditions [1] Group 2 - The company emphasizes its commitment to adhering to information disclosure regulations and will fulfill its disclosure obligations if there are clear acquisition plans that meet the disclosure standards [1] - Relevant information regarding acquisitions will be based on the company's official announcements [1]

Core Viewpoint - The company, Sairun Biotech, is currently the only domestic player developing antivenom serum for snake bites and is focusing on innovative broad-spectrum antibody technology to maintain its market leadership and address potential competition [1] Group 1: Company Strategy - Sairun Biotech is developing broad-spectrum antivenom antibodies using new antibody technology aimed at creating innovative drugs that are more universal, have fewer side effects, and are easier to administer [1] - The company aims to complement existing antivenom serums with its innovative products to better meet clinical medication needs in various application scenarios [1] Group 2: Market Position - Sairun Biotech acknowledges the presence of four types of venomous snakes in the market but emphasizes its first-mover advantage and technological barriers to sustain its competitive edge [1] - The company is aware of the potential for new entrants in the antivenom serum market and is strategizing to leverage its existing advantages [1]

Core Insights - The article highlights the significant advancements made by a Shanghai-based company, Sailun Biotech, in the field of biological toxin treatment, particularly in the development of antivenom for snake bites and other venomous injuries [1][2]. Group 1: Company Background and Development - Sailun Biotech was founded in 1999 and has evolved from a single product focus to a diversified portfolio, achieving a listing on the Sci-Tech Innovation Board [1][2]. - The company has been dedicated to the treatment of snake bites, which are a significant health crisis in China, with annual incidents ranging from 250,000 to 280,000 and a disability rate of 35.18% [2][3]. Group 2: Technological Advancements - The production of effective antivenom involves a complex and rigorous process, including toxin component analysis and large animal immunization, which Sailun Biotech has mastered over the years [3]. - The company is expanding its research and development efforts, with new projects underway for broad-spectrum antivenom and rapid diagnostic tests for snake venom, aiming to fill market gaps [3][4]. Group 3: Expansion into New Areas - Following success in snake antivenom, Sailun Biotech is venturing into the development of antivenom for bee stings, driven by a strong sense of social responsibility [4][5]. - The company is constructing a new research and production facility to enhance its capacity for large-scale production of these new products, expected to be completed by 2026 [4][5]. Group 4: Market Position and Future Plans - Sailun Biotech has made significant strides in innovation during the 14th Five-Year Plan, establishing platforms for rapid diagnostic tests and new antibody development [5][6]. - The company aims to enhance its market penetration and expand into international markets, leveraging its competitive pricing and quality advantages over foreign products [6][7].

Core Viewpoint - Shanghai is emerging as a global hub for biopharmaceutical innovation, with local companies leveraging innovation, transformation, and internationalization to enhance their competitiveness on the world stage [4][6]. Group 1: Innovation - Junshi Bioscience has focused on unmet clinical needs, successfully launching its PD-1 monoclonal antibody, which has reshaped the landscape for domestic innovative drugs in international markets [4][5]. - Fosun Pharma has achieved significant milestones in innovation, including the development of China's first self-developed CAR-T cell therapy product and the first PD-1 monoclonal antibody approved for first-line treatment of small cell lung cancer [8][9]. - The company has established a comprehensive innovation system, with over 12 innovative drugs launched during the 14th Five-Year Plan period, focusing on oncology, immune inflammation, and chronic diseases [11][12]. Group 2: Transformation - First Pharmaceutical has adapted to the challenges posed by e-commerce in the pharmaceutical retail sector by integrating smart healthcare services, revitalizing its traditional pharmacy model [5][30]. - Fosun Pharma's transformation journey aligns with the rapid evolution of China's innovative drug industry, emphasizing a combination of generics and original innovations [5][11]. - Seer Bio has expanded its research into broader biotoxin treatments after mastering snake venom therapies, indicating a strategic shift towards a wider range of biological toxin therapies [5][26]. Group 3: Internationalization - Fosun Pharma has successfully penetrated international markets, with its anti-tumor innovative drug, Slulizumab, approved in approximately 40 countries, showcasing the company's global strategy [12][13]. - Junshi Bioscience has transitioned from a "single-point breakthrough" to "platform innovation," with its core product, Toripalimab, now available in major markets including the US and EU [16][17]. - The company is building a global commercialization network through partnerships and local teams, aiming to enhance its international presence [22][23]. Group 4: Market Challenges and Opportunities - First Pharmaceutical faces significant challenges in the pharmaceutical distribution industry, including regulatory changes, evolving sales models, and increased consumer expectations for professional services [32][33]. - Despite these challenges, First Pharmaceutical has reported substantial revenue growth, with sales increasing from 1.398 billion yuan in 2021 to 1.915 billion yuan in 2024 [32]. - The company is strategically focusing on the silver economy, aiming to develop integrated services for the elderly, aligning with national policies on aging [34][35].

Core Viewpoint - Jiangxi Biological has submitted its application for listing on the Hong Kong Stock Exchange, marking its third attempt to go public and its second attempt after transitioning from the A-share market. The company is the largest supplier of Tetanus Antitoxin (TAT) in China and globally, with significant revenue growth driven by increased sales, particularly in overseas markets [1][2]. Group 1: Company Performance - In the first half of 2025, Jiangxi Biological achieved revenue of 99.704 million yuan, a year-on-year increase of 12.96%, and a net profit of 36.838 million yuan, up 118.02% year-on-year. The growth in revenue is attributed to increased sales of core products, especially exports to the Philippines and Ethiopia [1]. - From 2022 to 2024, Jiangxi Biological's annual revenue was 142 million yuan, 198 million yuan, and 221 million yuan, with a compound annual growth rate (CAGR) of 24.7%. During the same period, profits were 26.468 million yuan, 55.481 million yuan, and 75.14 million yuan, with a CAGR of 68.5% [2]. Group 2: Market Position - Jiangxi Biological holds a market share of 65.8% in China and 36.6% globally for TAT by 2024. The company has maintained over 50% market share in the Chinese TAT market for 18 consecutive years [2]. - The global demand for human antiserum is expected to grow at a CAGR of 4.9% from 2019 to 2024, reaching 821 million USD by 2028, while the Chinese market is projected to grow at a CAGR of 5.9%, reaching 132 million USD by 2028 [2]. Group 3: International Expansion - In 2024, Jiangxi Biological's total sales of human TAT reached 25.4 million doses, with 13.2 million doses sold in China and 12.2 million doses exported. In the first half of 2025, total sales were 12.2 million doses, with 5.8 million sold in China and 6.4 million exported [3]. - The company has exported human TAT to over 30 countries and regions in Asia and Africa, nearly monopolizing the export market in this field [3]. Group 4: Future Plans - The funds raised from the IPO will be used to further develop antivenom products, expand production facilities, and optimize production technology. The company plans to establish new production bases in Jiangxi and Inner Mongolia and will also invest in hiring new sales and marketing personnel [3]. Group 5: Company History and Management - Jiangxi Biological has a history dating back to 1969 and has undergone several transformations, becoming a modern biopharmaceutical company with over 50 years of research history. The company is currently led by a young management team, including the 29-year-old chairwoman, Jing Yue [4][5][6].

Core Viewpoint - Jiangxi Biological, the largest provider of human tetanus antitoxin in China, has officially submitted its IPO application to the Hong Kong Stock Exchange, showcasing rapid revenue growth but facing significant risks due to reliance on a single product and slow R&D progress [1][3][5]. Financial Performance - Jiangxi Biological's total revenue increased from 142 million yuan in 2022 to 221 million yuan in 2024, with profits rising from 26.5 million yuan to 75.1 million yuan, reflecting a compound annual growth rate (CAGR) of 68.5% [1][3]. - The revenue from human TAT accounted for over 90% of total income during the same period, with sales figures of 133 million yuan, 184 million yuan, and 206 million yuan respectively [3][4]. Product Dependency and Market Risks - The company heavily relies on human TAT, which poses operational risks due to potential changes in healthcare policies that could affect pricing and sales [3][4]. - Despite being included in the national medical insurance directory, any removal could significantly impact sales and profitability [3]. International Market Strategy - To capture markets in Southeast Asia and Africa, Jiangxi Biological has adopted a "low-price for market share" strategy, which has reduced profit margins significantly [4]. - The average export price of human TAT is approximately 3.6 yuan per unit, only 30% of the domestic average price, leading to a gross margin of 60.8% compared to 84.3% domestically [4]. R&D Pipeline and Challenges - The company is expanding its product line to include human antivenom products, but the R&D progress is slow, with significant delays in clinical trials for new products [5][6]. - R&D expenditures decreased by 43.54% in 2024, falling below distribution and administrative costs, indicating a lack of investment in innovation [6][7]. Market Growth Outlook - The human TAT market in China is projected to grow from 21.6 million USD in 2019 to 33.5 million USD in 2024, with a declining growth rate expected in the coming years [7]. - Without new growth points, Jiangxi Biological may face challenges in sustaining its growth trajectory [7].

Core Viewpoint - Jiangxi Biological has submitted a listing application to the Hong Kong Stock Exchange, with CICC and China Merchants Securities International as joint sponsors [1] Company Overview - Jiangxi Biological is the largest provider and exporter of human TAT (tetanus antitoxin) in China and one of the largest globally, holding a global market share of 36.6% and a domestic market share of 65.8% in 2024 [1] - The company possesses a comprehensive anti-serum platform that includes products such as human TAT, veterinary TAT, and equine chorionic gonadotropin (PMSG), with plans to expand into snake antivenom and rabies immunoglobulin products [1] - Jiangxi Biological has a global sales and distribution network covering over 23,500 medical institutions in China, including more than 1,500 tertiary medical institutions [1] Industry Insights - According to Frost & Sullivan, the global human anti-serum market has grown from USD 321 million in 2019 to USD 409 million in 2024, with a compound annual growth rate (CAGR) of 4.9% [1] - The market is projected to continue increasing to USD 821 million by 2028 and reach USD 2.095 billion by 2033 [1]

Group 1 - The company, Sairun Biotech (688163.SH), has stated that it currently has no plans to export its anti-snake venom serum [1]